Cancer Genetics Sharply Higher After Interpace Buys Biopharma Unit

Cancer Genetics (NASDAQ:CGIX) shares are trading sharply higher after Interpace Diagnostics (NASDAQ:IDXG) said it purchased the Biopharma Services unit of the Cancer Genetics.

Interpace Diagnostics shares are also trading higher after Ampersand Capital Partners agreed to invest $27 million in the company in two tranches of newly issued convertible preferred stock.

Cancer Genetics shares are up 53% at 27 cents in Tuesday’s pre-market session. The stock has a 52-week high of $1.30 and a 52-week low of 15 cents per share.

Interpace Diagnostics shares are up 3.8% at 72 cents in Tuesday’s pre-market session. The stock has a 52-week high of $1.78 and a 52-week low of 67 cents per share.

Related Links:

JPMorgan Q2 Earnings Beat Estimates

Johnson & Johnson Trades Higher On Q2 Earnings Beat